ACAD - ACADIA Pharmaceuticals Inc.
| Previous Close | 51.40 |
| Open | 51.13 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 2200 |
| Day's Range | 47.88 - 51.40 |
| 52 Week Range | 14.01 - 53.70 |
| Volume | 1,686,460 |
| Avg. Volume | 2,261,301 |
| Market Cap | 7.382B |
| Beta (3Y Monthly) | 2.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Benzinga
The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )(presented ...
- Barrons.com
A 60% Tumble for Sage Therapeutics, and Two More Numbers to Know
Another biotech company, (ACAD) (ACAD), also saw its stock jump 14%. There is sure to be more big biotech news coming up. It makes sense for GM to pair up with LG Chem (051910.Korea), rather than go it alone.
- Insider Monkey
Hedge Funds Snapped Up ACADIA Pharmaceuticals Inc. (ACAD) Before The Q4 Rally
The market has been volatile in the last few months as the Federal Reserve finalized its rate cuts and uncertainty looms over trade negotiations with China. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by more than 10 percentage […]
- Investor's Business Daily
Why This Highflying Biotech Stock Zoomed Near A Profit-Taking Zone
Shares of Acadia Pharmaceuticals popped Thursday after the biotech company's psychosis treatment succeeded in a late-stage study — sending Acadia stock near a profit-taking zone.
- Barrons.com
Biotech Stocks Are Making Wild Moves Amid a Deluge of Trial Data
Drug-trial news sent shares of Aurinia Pharmaceuticals soaring Thursday morning and Sage Pharmaceuticals tumbling.
- Benzinga
The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of ...
- Reuters
Acadia Pharma's psychosis drug proven better than placebo in dementia patients
Acadia Pharmaceuticals Inc said on Wednesday dementia patients taking its drug Nuplazid were nearly three times less prone to a psychotic relapse than those on placebo. The drugmaker's late-stage trial testing Nuplazid, stopped in September after positive results, enrolled 392 patients aged 74.5 years on average. Patients on the drug experienced a 65% reduction rate in relapses of dementia-related psychotic episodes, the company said.
- InvestorPlace
7 Exciting Biotech Stocks to Buy Now
Over the past 12 months, the Nasdaq Biotech Index (NBI) has kept up with the broader market, slightly outpacing the S&P 500, until the last few months.Certainly 2019 has been a bumpy ride. But it looks like the sector, especially thank to its larger firms, is finally hitting its stride. The index is rising and a growing number of mergers over the past couple years are starting to pay off.There are some amazing new technologies that are finally gaining traction on the medication side, which includes a long journey through U.S. Food and Drug Administration trials. It usually takes about 10 years and costs around $2 billion to get a drug through trials these days.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThat's a lot of commitment. And during that time, you need to develop a strong pipeline for future growth. * 7 Entertainment Stocks to Buy to Escape Holiday Blues At Growth Investor, we are focused on pure biotech stocks, not big pharma. These seven big biotech companies are driving cutting-edge therapies. These names are either currently thriving or well positioned for buyouts that would come with big premiums. Biotech Stocks to Buy: Galapagos (GLPG)Source: Shutterstock Galapagos (NASDAQ:GLPG) is a perfect example of the new wave in biotech. It uses adenoviruses -- viruses that usually cause respiratory illnesses -- to introduce human gene sequences to help or prevent certain proteins from multiplying.The formations of proteins play a critical role in a number of diseases, including cancer. They are also key in autoimmune diseases. And GLPG focuses on the latter.It has four drugs in clinical trials currently, and two of those are in Phase 3 trials. That is encouraging, since it is usually moving into Phase 3 trials where many drugs fall short.The stock is up a whopping 94% this year as trial results are driving price, yet its trailing price-to-earnings ratio is 38. It has a $12 billion market capitalization, so it's well funded. China Biologic Products (CBPO)Source: Shutterstock China Biologic Products (NASDAQ:CBPO) is one of China's leading biotech companies. Its work isn't fancy, but it's functional. And in a population of 1.4 billion people, high-quality drugs represent a huge step forward.China is very focused on developing its pharmaceutical and healthcare industry instead of relying on the U.S or Europe to sell it medicines. But this is a huge undertaking to start from nearly scratch.CBPO is one of the first to do it. It's not making cutting-edge drugs and doing breakthrough research -- it's focused on plasma-based biopharmaceutical products. These are fundamental for treatment of immune system disorders, epidemic diseases and disaster relief. * 10 Cheap Stocks to Buy Under $10 It gained a lot of attention last year when a consortium offered nearly $4 billion for the company. Its current market cap is $4.5 billion and the stock is up 54% year-to-date. That's the kind of momentum I like to see at Growth Investor, and there's still plenty of headroom here. Arrowhead Pharmaceuticals (ARWR)Source: Shutterstock Arrowhead Pharmaceuticals (NASDAQ:ARWR) works on novel drugs for intractable diseases. And that about sums up its focus.Right now, it has nine drugs in trials. Two of them are in Phase 3. One is for liver disease and the other for Hepatitis B. Most of its other drugs are focused on diseases affecting the liver. It also has one in trial for lung cancer and another for renal cell carcinoma.It is focused on using RNAi, or RNA interference, to prevent cells from expressing a specific gene, usually a gene linked to a disease. RNAi has been around for a long time, and ARWR has been around since 1989. But it's now coming into its own, as technologies have grown up around it.The stock is up a staggering 432% year-to-date, due to its own work and the interest that big pharma is now taking in the sector. With a $6.3 billion market cap, it would be an easy buy for a big firm looking to acquire a solid pipeline of RNAi drugs. Acadia Pharmaceuticals (ACAD)Source: Shutterstock Acadia Pharmaceuticals (NASDAQ:ACAD) focuses on central nervous system disorders. These range from schizophrenia to Parkinson's to major depressive disorder.It actually has a drug in the market. In 2016 Nuplazid was launched to help manage the hallucinations and disorientation sometimes experienced by Parkinson's patients. Second-quarter sales were $83 million, up 46% from the same quarter a year ago. That's more than $300 million a year, and growing.It has another drug that is wrapping up Phase 3 trials and is targeted at dementia-related psychosis. Yet another drug is halfway through Phase 3 trials focused on providing an adjunctive therapy for major depressive disorder.This firm isn't just about the future, it's succeeding in the market right now. And in a unique niche, no less. This niche will continue to grow as boomers age, so demographics are also on its side. That's the kind of growth potential I demand from stocks in any industry. * 9 Tantalizing Dividend Stocks for 2020 ACAD stock is up 182% year-to-date and with a $7 billion market cap, it's still the early days. Spark Therapeutics (ONCE)Source: Shutterstock Spark Therapeutics (NASDAQ:ONCE) is a gene therapy company that focuses on genetic diseases including blindness, hemophilia and neurodegenerative conditions.These can be good areas for a relatively young gene company to plant its flag, because they aren't usually filled with as much competition. That also means that during drug trials, its efficacies don't have to meet as high standards.ONCE just launched its first drug this year, Luxturna, for inherited retinal dystrophy, which ultimately leads to blindness. Sales and results have been positive. The company also has a licensing and development deal with Pfizer (NYSE:PFE) for a drug targeting hemophilia. And Novartis (NYSE:NVS) has control of European marketing for Luxturna.The stock is up 184% year-to-date and has a bright future if it can keep delivering. Zai Lab (ZLAB)Source: Shutterstock Zai Lab (NASDAQ:ZLAB) is a Chinese biotech that launched in 2014. But today, it has a $2.6 billion market cap. That's some pretty fast growth.Part of the reason is that Incyte Pharmaceuticals (NASDAQ:INCY), maker of the rheumatoid arthritis drug Jakafi, has become an investor. This partnership allows INCY to market its drug in China and gives ZLAB access to the U.S. market. At Growth Investor, we invest with an eye on macroeconomic trends, and these are the two markets exhibiting the strongest growth.Their product lines overlap as well, which has some strategic advantages. Both have products in autoimmune diseases, and ZLAB also is doing work in cancer and infectious diseases.ZLAB has 16 drugs in Phase 3 trials, with one, Optune, ready for market in Hong Kong. Its massive pipeline is especially attractive for a firm like INCY when looking at marketing some of these in the U.S. market. * 7 Top Stocks to Buy for 2020 The stock is up 73% year-to-date and could be a sleeping giant, if all unfolds according to plan. Natera (NTRA)Source: Shutterstock Natera (NASDAQ:NTRA) isn't a typical biotech in the sense that it develops drugs.Its niche is genetic testing. While you may think that begins and ends with prenatal testing for hereditary disorders and the like, the fact is, that's just the beginning.It can run testing on cancers so that oncologists can get an exact description of the cancer. Today, there are gene therapies and immuno-oncology therapies that can be used to help certain cancer patients. And that list is growing. Also, recurrence monitoring and treatment monitoring are much more targeted and accurate.Also, genetic testing can help make sure that transplants are more successful. For insurers and hospitals (as well as patients of course), a clean transplant means no issues with tissue rejection, infection or longer hospital stays.It might not have a sexy silver bullet in this sector, but it does have a great reputation.The stock is up 155% year-to-date. And given the lack of drama in the stock, its big growth could keep on going as long as the population continues to gray.All this gives you an idea of why these stocks rate so highly in my Portfolio Grader tool. And I've got more where that came from. There's a bigger, deeper tech trend going on that I'm even more excited about. 'The Mother of All Technologies'Up until now, technologies have certainly made our lives easier and more efficient … but with a lot of room for human error. People trip over cords, spill their coffee and get tired.Artificial intelligence does not.If that sounds futuristic, well then, the future is already here. If you use apps like Netflix (NASDAQ:NFLX), TurboTax, QuickBooks, Zillow (NASDAQ:Z) or even an email spam filter, then AI is already helping your day run more smoothly. And as scientists find even more applications for artificial intelligence -- from healthcare to retail to self-driving cars -- it's incredible to imagine how much data will be involved.To create AI programs in the first place, tech companies must collect vast amounts of data on human decisions. Data is what powers every AI system.So any one company that can help with customers' data issues is the one company that's most worth investing in.You don't need to be an expert to take part. I'll tell you everything you need to know, as well as my "buy" recommendation, in Growth Investor. My No. 1 stock for the AI trend is still under my buy limit price -- so you'll want to sign up now. Get in while it's still cheap.Click here for a free briefing on this groundbreaking innovation.Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system -- with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the "Master Key" to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Things to Watch for into 2020 for Safer Income & Growth * 7 Entertainment Stocks to Buy to Escape Holiday Blues * 5 "Strong Buy" Biotech Stocks With More Than 80% Upside The post 7 Exciting Biotech Stocks to Buy Now appeared first on InvestorPlace.
- Benzinga
The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
Biotech stocks advanced in the holiday-shortened week, with upside driven mainly by the broader market strength. Reflecting the extreme volatility in the space, a few stocks gyrated wildly in reaction ...
- TipRanks
3 Monster Growth Stocks That Are Still in the Buy Zone
With the holiday season kicking off, investors are shopping the Street for growth stocks. Stocks of this kind have a clear runway for growth, capable of delivering massive returns in the years to come. No wonder they are topping wish lists. However, in a year that has seen the market reach record highs, tracking down these names is becoming harder and harder to do. But don’t sound the alarm bells just yet. Wall Street pros remind investors that stocks with outsized growth prospects are still out there. In an attempt to lock down these compelling investment opportunities, we turned to TipRanks. The platform’s Stock Screener tool was able to scan the Street for the crème-de-la-crème. We mean the tickers offering up serious upside potential from current levels. Let’s get started. GDS Holdings Ltd (GDS)At a 103% year-to-date gain, all eyes are on GDS Holdings. This combined with a solid Q3 performance and strong long-term growth narrative has made the Chinese data center developer and operator a must-have name among several analysts. During the third quarter, the company saw revenue of RMB1,066 million, inching past the consensus estimate by about a percent. On top of this, service revenue increased 41% year-over-year and net loss narrowed from the prior-year quarter. That being said, Cowen & Co. analyst Colby Synesael points to its positioning in terms of demand as a key takeaway. “We believe the company continues to be well positioned in what is arguably the strongest data center market in the world and is taking the right steps to secure significantly more supply in its major markets as it prepares for even stronger demand in 2020,” he commented. Despite the five-star analyst’s prediction of continued macro and trade-driven volatility, he believes shares are set to climb higher in 2020. Taking this into consideration, Synesael reiterated his Outperform rating and bumped up the price target from $53 to $65. This bolstered target lends itself to a 39% potential twelve-month gain. (To watch Synesael’s track record, click here)Meanwhile, RBC Capital’s Jonathan Atkin cites the development pipeline as placing GDS on an upward trajectory. With GDS recently getting the go-ahead for 13,000 square meters of downtown capacity in Shanghai and its potential purchase of a second site in Hong Kong, total capacity lands at 230,000 square meters. “We believe, based on our discussions with industry contacts, that there is significant progress yet to come for additional edge-of-town deployments as well as new Tier 1 markets,” he noted. As a result, Atkin is staying with the bulls. Not to mention he lifted the price target by 40% to $62, indicating 32% upside potential. (To watch Atkin’s track record, click here)Similarly, the rest of the Street has been impressed by GDA. 100% Street support implies a clear message: the stock is a Strong Buy. In addition, the $61 average price target puts the upside potential at 31%.(See GDS Holdings stock analysis on TipRanks) ACADIA Pharmaceuticals, Inc. (ACAD)ACADIA Pharmaceuticals wants to help patients battling central nervous system (CNS) disorders. When we say this name has soared year-to-date, we aren’t kidding. We’re talking 180% here. Still, analysts think that this is just the beginning.On November 25, ACAD released topline results from the ADVANCE Phase 2 trial of its pimavanserin drug in schizophrenia patients. According to the data, patients given the treatment witnessed a great improvement in Negative Symptom Assessment-16 (NSA-16) total score compared to the placebo. However, the results were somewhat of a mixed bag as it failed to demonstrate a superior performance vs the placebo in terms of the Personal and Social Performance (PSP) scale. Nonetheless, Cowen’s Ritu Baral maintains a bullish thesis. “Overall, we view these results to have little impact on ACAD shares due to the earlier stage of this program and the smaller market size of schizophrenia patients with predominant negative symptoms relative to pimavanserin's new opportunity in Dementia-related psychosis (DRP),” she explained. The five-star analyst goes on to cite the Phase 3 HARMONY study in DRP patients as an upcoming catalyst. If this wasn’t promising enough, its trofinetide drug to treat patients with Rett Syndrome could also drive substantial gains. Rett Syndrome is a primarily female congenital neuro-developmental CNS disorder affecting cognition and sensorimotor function. Given that the drug demonstrated statistically significant results in a Phase 2 study as well as its potential to treat Fragile X Syndrome or traumatic brain injuries, Baral kept the recommendation as Outperform. Based on the $66 price target, she sees 46% upside potential in store. (To watch Baral’s track record, click here)In general, Wall Street likes what it’s seeing. 11 Buys and 2 Holds received in the last three months add up to a Strong Buy analyst consensus. At the $56 average price target, shares could surge 23% in the next twelve months. (See ACADIA Pharmaceuticals stock analysis on TipRanks) Pegasystems Inc. (PEGA)Pegasystems offers cloud-based software for customer engagement and other operational needs, with its low-code application development platform allowing organizations to quickly build apps to meet their customer and employee requirements. Considering the noteworthy 62% jump year-to-date, one analyst is betting that PEGA will come out on top in the long-run.Wedbush analyst Steven Koenig was impressed by PEGA’s third quarter results. Despite the fact that investments in cloud infrastructure and government certifications weighed on EPS, annual contract value growth of 20% year-over-year and a 7% revenue gain landed right in-line with consensus estimates. While PEGA may be impacted by the shift to a cloud-first model, the analyst expects this change to pay off long-term, deeming the software company a “Wedbush Best Idea”.“Investments in sales talent and capacity should drive better penetration of large accounts, perhaps the key to lifting underlying growth rates beyond the 20% level. With shares trading at 5.6x EV/FY20E revenue and key metrics inflecting positively, we see PEGA as a top pick into FY20 for GARP-oriented software investors,” he wrote in a note to clients. Bearing this in mind, Koenig tells investors his conclusion that PEGA will ultimately outperform remains unchanged. Along with the recommendation, the five-star analyst kept the price target at $95. This conveys his confidence in PEGA’s ability to rise 22% in the coming twelve months. (To watch Koenig’s track record, click here) Looking at the consensus breakdown, it has been relatively quiet in terms of analyst activity. In the previous three months, PEGA racked up 1 Buy rating, giving it a Moderate Buy consensus. Additionally, the average price target of $95 implies 22% upside potential. (See Pegasystems stock analysis on TipRanks)
- Zacks
What Makes Acadia Pharmaceuticals (ACAD) a Strong Momentum Stock: Buy Now?
Does Acadia Pharmaceuticals (ACAD) have what it takes to be a top stock pick for momentum investors? Let's find out.
- TEST Business Wire Releases
ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced positive top-line results from its ADVANCE study, a 26-week, randomized, double-blind, placebo-controlled study in 403 patients. ADVANCE evaluated the efficacy and safety of adjunctive pimavanserin treatment in patients with predominantly negative symptoms of schizophrenia who have achieved adequate control of positive symptoms with their existing antipsychotic treatment. No drug is approved by the FDA for the treatment of the negative symptoms of schizophrenia.
- Zacks
Top Ranked Momentum Stocks to Buy for November 25th
Top Ranked Momentum Stocks to Buy for November 25th
- Investopedia
The Medicines Company Soars Amid Acquisition Whispers
The Medicines Company climbed to an all-time high Tuesday after takeover rumors surfaced. Play the momentum using these tactical ideas.
- Zacks
Medtronic (MDT) to Report Q2 Earnings: What's in Store?
In the fiscal second quarter, Medtronic (MDT) is expected to have registered strong growth in its ICD and CRT product lines.
- Zacks
The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
- Investor's Business Daily
IBD Stock Of The Day Breaks Out As It Stares Down A Massive Opportunity
Acadia Pharmaceuticals is the IBD Stock Of The Day as investors look ahead to a presentation of the biotech company's psychosis treatment, a drug known by the test name of pimavanserin.
- Zacks
4 Biotech Stocks That Could Keep Beating Wall Street
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
- Simply Wall St.
Have Insiders Been Selling ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
- Zacks
Acadia (ACAD) Upgraded to Buy: Here's Why
Acadia (ACAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Thomson Reuters StreetEvents
Edited Transcript of ACAD earnings conference call or presentation 30-Oct-19 8:30pm GMT
Q3 2019 ACADIA Pharmaceuticals Inc Earnings Call
- Zacks
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of 29.27% and 6.79%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Cigna (CI) to Report Q3 Earnings: What's in the Offing?
Cigna (CI) Q3 earnings are likely to have benefited from higher contribution across all its segments and effect of share buyback.
- Zacks
Will Nuplazid Aid Growth for ACADIA (ACAD) in Q3 Earnings?
During ACADIA's (ACAD) third-quarter 2019 conference call, investor focus will be on the sales figure of its only marketed drug Nuplazid and its label expansion studies.
